Abstract - 603255 Disclosed is the compound 2-(3-(cyclopropylmethyl)-2-oxo-imidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of the compound 2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof optionally in combination with a therapeutic...

PURPOSE: A composition containing Dendrobium moniliforme is provided to prevent relieve or treat PPAR activation regulation-related diseases including obesity metabolic diseases and cardiovascular diseases. CONSTITUTION: A composition for preventing or treating PPAR activation regulation-related diseases contains Dendrobium moniliforme as an active ingredient. A composition for health functional food for preventing or treating PPAR activation regulation-related diseases contains Dendrobium monil...

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1 R2 R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases especially Type II diabetes and other diseases as set out herein employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such...

The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator .

PURPOSE: A pharmaceutical composition containing a thiazolidinedione-based drug for preventing and treating Alzheimer's disease is provided to enhance LRP1 expression and the discharge of beta-amyloid into the blood. CONSTITUTION: A pharmaceutical composition for treating neurological disorders contains a thiazolidinedione-based drug as an active ingredient. The thiazolidinedione-based drug includes rosiglitazone pioglitazone or troglitazone. The pharmaceutical composition enhances the LRP1 expr...

C: \NRPortbl\DCC\DAR\489270_l.DOC-17 12/2012 Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions kits and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs. Hexahydrocolupulone _-^-7.1 0.57 Spent Hops : 1.11 Beta-Acids 1 .24 Alpha Acids sw ____ _ -' 1 1.45 -_- I _ _ ii _ Xanthohumol rrImm mm - 1.46 Hexahydroisoalpha acids Ir:".E 2 Tetrahydroi...

595024 Disclosed herein is a compound which is NN-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbomoyl-4-yloxy)pyrimidine-2-carboxamide a pharmaceutical composition comprising it and a pharmaceutical composition further comprising an anti-obesity agent and an anti-diabetic agent. Wherein said anti-obesity agent is selected from the group consisting of dirlotapide mitratapide implitapide lorcaserin cetilistat PYY3-36 naltrexone oleoyl-estrone obinepitide pramlintide tesofensine leptin liraglut...

This invention provides a process for reducing an exocyclic double bond at the 5-position of a thiazolidinedione moiety of a thiazolidinedione precursor comprising the steps of: a) preparing a solution or suspension of the thiazolidinedione precursor in a non-ether solvent medium with a base and b) combining the solution or suspension with a dithionite source. Preferred solvent media include aqueous NN-dimethylformamide. Sodium dithionite is a preferred dithionite source. In particular the appli...